Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women.
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oxytocin-related, posterior pituitary hormone vasopressin has a powerful effect on the uterus via vasopressin V 1a receptors (6, 7) . This hormone possibly also contributes to the induction of labor, as it is released during stressful situations such as labor (8) , and the vasopressin V 1a receptors are upregulated at the onset of labor contractions (4, 5) . Oxytocin also binds to the vasopressin V 1a receptor to some extent, as does vasopressin to the uterine oxytocin receptor of pregnant women (7, 9) .
In women with primary dysmenorrhoea, myometrial hyperactivity and reduced uterine blood flow have been demonstrated to be related to the pain (10) . Increased vasopressin secretion is apparently an important pathophysiological factor for these changes (11) (12) (13) .
Compounds that block the oxytocin and the vasopressin V 1a receptors of the uterus are of potential therapeutic interest for inhibiting the uterine hyperactivity of preterm labor (14, 15) and primary dysmenorrhoea (16, 17) . Animal experiments are of little value for the prediction of such effects with these compounds in the human in relation to these two conditions (18) . Furthermore, results from experiments with isolated human myometrium only give limited guidance (18) . However, in the development of the peptide oxytocin and vasopressin V 1a antagonist, 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-oxytocin, which was recently approved in Europe for the inhibition of preterm labor contractions (14, 15) , results in non-pregnant volunteers in vivo gave important leads for the further clinical development of the drug in this condition (19, 20) . Studies with oxytocin and vasopressin V 1a antagonists in vivo in the human may also assist in the delineation of the effects of oxytocin and vasopressin per se on uterine contractions (9, 21, 22) . In the present investigation, we examined the effect of SR49059, a preferential vasopressin V 1a -receptor antagonist compared with its effect on oxytocin (7), on oxytocin-and vasopressininduced uterine contractions in healthy, sterilized, non-pregnant women.
Materials and methods

Material
Sixteen healthy women, permanently sterilized by tubal division during laparoscopy, participated in this study. Their mean age was 40.4 years (range 33-44 years), and they had a body mass index with a mean of 24.6 kg/m 2 (range 21-30 kg/m 2 ). The women menstruated regularly, had no menstrual pain and also had no history of gynecologic health problems. The Ethics committee of the University of Lund, Sweden approved the study protocol. The nature and purpose of the investigation was described to each woman verbally and in writing, and they all gave their written consent to participation. Before inclusion, all subjects were found medically healthy at a screening visit with general and gynecologic examinations, measurements of plasma and urine safety parameters, and serology for hepatitis-B and human immunodeficiency virus 1 and 2 antibodies.
Recordings of myometrial contractility were obtained on days 1, 2 or 3 of two usually consecutive menstruations and usually on the corresponding cycle days in each woman. Before each recording, an electrocardiogram was obtained. Blood pressure and pulse rate were noted repeatedly during the experiment and any adverse events recorded. At a follow-up visit, 7 days after the second recording, electrocardiogram, vital signs and adverse events were again recorded and routine safety plasma and urine parameters obtained.
Myometrial contractile activity was measured by recording intrauterine pressure via a microtransducer catheter as previously described (22) . The intrauterine pressure signals were analyzed using a computer (Polygraaf and Software from Synetics AB, Stockholm, Sweden). The area between the pressure curve and zero level of pressure over 10-min periods was calculated. Before each recording, an indwelling venous catheter was also inserted in each arm, one for injections and one for blood sampling.
In a randomized order with four subjects in each group, SR 49059 was given in a single, oral dose of 0 (placebo), 25 , 75 or 200 mg. Each subject received the same treatment during both recording sessions. The drug was administered in soft gelatine capsules containing 25 mg each. At the first recording session, each woman received intravenous bolus injections over 1 min of arginine vasopressin (Pitressin 1 , Parke Davis, Berlin, Germany) at a dose of 10 pmol/kg body weight. At the second session, the subject received intravenous bolus injections over 1 min of oxytocin (Syntocinon 1 , Sandoz, Basel, Switzerland) at a dose of 50 pmol/kg body weight. The agonist was injected four times at each recording, 1 h before administration of the study drug (T-1 h) and 1 (T1 h), 2 (T2 h) and 4 (T4 h) hours thereafter.
During the experiments, blood samples for the estimation of plasma concentrations of oxytocin and vasopressin were taken 5 min before and after the first (T-1 h) and the second (T1 h) injection of the agonists. The samples were taken in chilled tubes, immediately centrifuged for 10 min at 4 C and at 2000 g, the plasma was then stored deep-frozen at À 20 C until assay (kindly performed by Dr D. G. Bichet, Department of Clinical Chemistry, Hôpital de Sacre Coeur, Montreal, Canada).
The plasma concentrations of SR 49059 were measured in samples obtained before and at 0.5, 1, 1.5, 2, 3, 4 and 5 h after intake of the study drug. SR 49059 was determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method under the responsibility of the Clinical Metabolism and Pharmacokinetics Department of Sanofi-Synthelabo Pharmaceuticals Inc. Malvern, Pennsylvania, USA. The limit of quantification (LOQ) was 0.5 ng/ml.
At each recording session, the plasma and urine parameters as during the screening visit, except serology, were measured. Electrocardiograms were obtained 1 h before the first injection of arginine vasopressin and after each experiment. Blood pressure recordings were obtained at 60-min intervals throughout the experiments, the pressure being measured immediately before each agonist injection.
The purpose of this study was to determine potency of the compound against two challenge criteria (AVP-induced uterine contractions and OT-induced uterine contractions) using dosedependent parameters such as inhibition concentration and/or inhibition dose. Therefore, the number of volunteers recruited was not essentially based on any formal power calculation. The area under the recording curve (AUC) of intrauterine pressure was calculated for 10-min periods from 0 to 50 min after each agonist injection. The 10 min before the next bolus was taken as baseline for the subsequent agonist challenge. Results were analyzed using an ANOVA test following the model: treatment sequence þ period þ treatment, sequence Â period þ subject representing the effect of treatment. Differences between the two treatments were assessed using a Fischer-Snedecor test. The statistical package used for analysis was SAS version 6.9 (SAS Institute Inc., Cary, North Carolina, USA). A two-sided t-test of statistical significance was applied at the 5% level.
Results
Sixteen subjects participated in the first recording and 11 in the second. One subject discontinued because of an adverse event (on placebo) and four, one in each treatment group, because the study was stopped as requested by the Sponsor for a potential safety reason.
The plasma levels of oxytocin and vasopressin before and after the first and second injections with the different concentrations of SR 49059 and placebo are shown in Table I . The differences between dose groups were small, although oxytocin at a fivefold higher dose caused a larger increase in plasma levels than the corresponding vasopressin injections. The maximum plasma concentration of the study drug appeared to be dose related, with mean maximal values (SD) 62.0 (46.8), 163.7 (107.9) and 468.0 (116.6) ng/ ml in the 25, 75 and 200 mg dose groups, respectively, in the Period 1 with vasopressin and 34.4 (23.9), 116.7 (140.8) and 418.0 (320.0) ng/ml, respectively, in the Period 2 with oxytocin. T max was observed at approximately 1 h. A representative recording of the effect of oxytocin and vasopressin injections in a subject receiving 25 mg of SR 49059 and of vasopressin in a subject who received placebo is shown in Fig. 1 . The results in AUCs of each 10-min period up to 50 min after injection of both agonists and with all study drug doses are shown in Fig. 2 . Finally, a summary of the difference in baseline corrected cumulative AUCs (0-50 min) for each dose of SR49059 versus placebo by challenge is shown in Table II . There was a statistical difference between challenges, cumulative AUCs being higher with vasopressin than with oxytocin (p ¼ 0.001), in spite of a fivefold higher intravenous dose of oxytocin (Figs 1 and 2) . Difference estimates in baseline-corrected cumulative AUC (0-50 min) between challenges for each SR 49059 dose indicated that the cumulative AUCs for vasopressin were higher on average compared with oxytocin (Table II) . SR 49059 caused a dose-dependent inhibition in cumulative AUCs for vasopressin, whereas no such effect was observed for oxytocin ( Figs 1 and 2 , Table II) .
A summary of the difference in baselinecorrected supine systolic and diastolic blood pressures for each SR 49059 dose versus placebo by challenge is shown in Table III . In subjects receiving vasopressin, diastolic blood pressures were significantly lower with each of the SR 49059 doses compared with that in the placebo group (Table III) .
A total of four subjects experienced adverse events. These were headaches (six episodes in two subjects in the 25 mg SR group with one of the two subjects noting hot flushes and chest pain), nausea (one subject in the Placebo group) and tachycardia (one subject in the 200 mg SR group). None of the events were considered related to SR 49059, but to vasopressin-or oxytocin-concomitant administration. There were no abnormalities reported in laboratory parameters.
Discussion
As the study was stopped, the information obtained is somewhat limited. However, the present results confirmed the high potency of vasopressin on uterine activity in non-pregnant women (19) (20) (21) (22) . In spite of a five times lower dose than that of oxytocin, the uterine effects were higher in the vasopressin group. This is also in agreement with the five times higher myometrial content of vasopressin V 1a receptors than of oxytocin receptors in the non-pregnant condition (21) . Furthermore, the vasopressin V 1a receptor concentration and the uterine potency of this hormone increase premenstrually (21) . In pregnancy, oxytocin appears to be more important as a uterine stimulant and, in fact, is centrally involved in mechanisms of labor (for review, see 23). It is known, however, that oxytocin may influence not only the oxytocin but also the vasopressin V 1a receptor, both in the pregnant and in the non-pregnant uterus, and that vasopressin has an effect on both receptors as well (5, 7, 21) . The potency of vasopressin on the pregnant human uterus appears to be slightly higher than that of oxytocin but the number of binding sites for oxytocin and vasopressin seems to be approximately the same (5) . There is a tendency for an increase in density of oxytocin and vasopressin V 1a receptors at the onset of labor preterm and at term. The importance of both the oxytocin and the vasopressin V 1a receptor in uterine activation is supported by the studies of gene expression for these receptors (24) . Although the present study was not completed as planned, we observed a dose-dependent inhibition by SR 49059 of vasopressin-induced contractions, whereas no such effect was observed against oxytocin. This finding is in agreement with the previously observed sevenfold higher binding affinity of SR 49059 to vasopressin V 1a receptors compared with oxytocin receptors (23) . It can be concluded that SR 49059 is a powerful vasopressin V 1a receptor inhibitor, whereas the effect on the oxytocin receptor is weak or inexistent.
Diastolic supine blood pressure was significantly lower after pretreatment with SR 49059. This finding emphasizes the particular importance of vascular effects of vasopressin. Some indications in fact exist that there are slight differences in the myometrial and vascular vasopressin V 1a receptors (25) and SR 49059 appears to be more effective on the latter ones. Such an effect may be of particular interest in conditions with disturbed uterine circulation, i.e. primary dysmenorrhoea.
